Diagnostics and Therapeutics for HIV: Global Markets
The global market for HIV therapeutics and diagnostics is expected to grow to $18.2 billion in 2013 and $19.6 in 2018, with a compound annual growth rate (CAGR) of 1.5%.
This report provides:
An overview of the global market for HIV therapeutics and diagnostics
Analyses of global market trends, with data from 2013, and estimates and projections of CAGRs through 2018.
Discussion of improvements in advanced treatments and diagnostic methods.
Examination of cost implications for treatments accross a wide range of countries
A look at ongoing research and the future direction of the market.
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing and prophylaxis of HIV/AIDS. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and considered assessment of the regulatory environment, health-care policies, demographics and other factors that directly affect the HIV/AIDS market. The wider economic environment is also taken into account.
REASONS FOR DOING THE STUDY
HIV/AIDS is one of the most catastrophic threats to human health throughout the world. Advanced treatment options and improved methods of diagnosis have helped to moderate the growth of the epidemic and this has presented opportunities for companies prepared to engage actively in this field. However, the management of HIV/AIDS is still, in many respects, an unfulfilled market and there is an ongoing, urgent need for promising new research directions as well as optimal exploitation of the treatment and diagnostic options already developed. In this dynamic and continually evolving marketplace, there is a need for an up-to-date, comprehensive appraisal covering both strategic and tactical options confronting the pharmaceutical industry.
This report is intended for large companies, small and medium enterprises (SMEs), government organizations and nongovernmental organizations (NGOs) operating in the HIV/AIDS space. Specifically, this report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
SCOPE AND FORMAT
This report summarizes the market of HIV/AIDS products and discusses the present status and evolution of antiretroviral (ARV) drugs with analyses by selected major national markets. The latest treatment and diagnostic options and practices are described and their cost implications clarified, especially in the context of treatment affordability in countries of widely varying economic status. The emergence of a considerable generic medicine component in the marketplace, alongside the presence of original branded medicines, is discussed. The current market for antiretroviral therapies is analyzed, with breakdowns by drug categories, and the leading drugs of 2012 are discussed. Five-year forecasts are provided with reasonable explanations. This report also summarizes the research efforts in early HIV prophylaxis, including pre-exposure prophylaxis, post-exposure prophylaxis and prevention of HIV transmission from mother to infant. Finally, major research efforts for developing HIV vaccines are summarized and promising directions are identified.
Both primary and secondary research methodologies were used in preparing this study. Primary research included interviews with leading individuals in pharmaceutical companies and industry associations. Primary sources of published data included company annual reports, SEC filings, and government and industry publications. Secondary sources consisted of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources and critically assessed by BCC Research. The global HIV market is estimated based on sales revenue generated by antiretroviral drugs.